Building on this, Fässler, Mirjam, and their colleagues conducted a cohort experiment hypothesizing that pre-existing antibodies against more widespread antigens might correlate with the clinical outcomes of melanoma patients undergoing PD-1/PD-L1 and CTLA4 treatment. The gene discussed is PDCD1; the disease is melanoma.